vs
Celularity Inc（CELU）与High Roller Technologies, Inc.（ROLR）财务数据对比。点击上方公司名可切换其他公司
High Roller Technologies, Inc.的季度营收约是Celularity Inc的1.2倍（$6.3M vs $5.3M），High Roller Technologies, Inc.净利率更高（58.4% vs -436.7%，领先495.1%），High Roller Technologies, Inc.同比增速更快（-16.4% vs -43.2%）
Celularity Inc是一家临床阶段生物技术企业，专注于开发胎盘来源的即用型细胞疗法与免疫疗法，用于治疗癌症、自身免疫性疾病及退行性疾病，主要面向美国市场，产品管线覆盖肿瘤学、再生医学、传染病等领域。
该企业主营游乐设施业务，凭借气动驱动技术打造各类游乐设备，专业从事过山车设计研发，在游乐设施设计制造领域拥有相关技术积累与行业经验。
CELU vs ROLR — 直观对比
营收规模更大
ROLR
是对方的1.2倍
$5.3M
营收增速更快
ROLR
高出26.7%
-43.2%
净利率更高
ROLR
高出495.1%
-436.7%
损益表 — Q3 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $5.3M | $6.3M |
| 净利润 | $-23.1M | $3.7M |
| 毛利率 | 26.1% | — |
| 营业利润率 | -244.1% | 1.3% |
| 净利率 | -436.7% | 58.4% |
| 营收同比 | -43.2% | -16.4% |
| 净利润同比 | -43.3% | 831.9% |
| 每股收益（稀释后） | $-0.88 | $0.39 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CELUROLR
| Q3 25 | $5.3M | $6.3M | ||
| Q2 25 | $5.7M | $6.9M | ||
| Q1 25 | $11.4M | $6.8M | ||
| Q4 24 | $18.1M | — | ||
| Q3 24 | $9.3M | $7.5M | ||
| Q2 24 | $12.1M | — | ||
| Q1 24 | $14.7M | — | ||
| Q4 23 | $12.1M | — |
净利润CELUROLR
| Q3 25 | $-23.1M | $3.7M | ||
| Q2 25 | $-24.5M | $-592.0K | ||
| Q1 25 | $-19.8M | $-3.3M | ||
| Q4 24 | $-13.3M | — | ||
| Q3 24 | $-16.1M | $-501.0K | ||
| Q2 24 | $-6.5M | — | ||
| Q1 24 | $-22.0M | — | ||
| Q4 23 | $9.5M | — |
毛利率CELUROLR
| Q3 25 | 26.1% | — | ||
| Q2 25 | 8.6% | — | ||
| Q1 25 | 68.9% | — | ||
| Q4 24 | 59.5% | — | ||
| Q3 24 | 58.2% | — | ||
| Q2 24 | 82.5% | — | ||
| Q1 24 | 88.8% | — | ||
| Q4 23 | 20.7% | — |
营业利润率CELUROLR
| Q3 25 | -244.1% | 1.3% | ||
| Q2 25 | -276.6% | -7.2% | ||
| Q1 25 | -91.8% | -47.4% | ||
| Q4 24 | -51.2% | — | ||
| Q3 24 | -124.0% | -6.3% | ||
| Q2 24 | -84.0% | — | ||
| Q1 24 | -50.2% | — | ||
| Q4 23 | — | — |
净利率CELUROLR
| Q3 25 | -436.7% | 58.4% | ||
| Q2 25 | -427.5% | -8.5% | ||
| Q1 25 | -172.9% | -48.4% | ||
| Q4 24 | -73.3% | — | ||
| Q3 24 | -173.2% | -6.7% | ||
| Q2 24 | -53.6% | — | ||
| Q1 24 | -149.9% | — | ||
| Q4 23 | 78.8% | — |
每股收益（稀释后）CELUROLR
| Q3 25 | $-0.88 | $0.39 | ||
| Q2 25 | $-1.02 | $-0.07 | ||
| Q1 25 | $-0.84 | $-0.39 | ||
| Q4 24 | $-0.58 | — | ||
| Q3 24 | $-0.73 | $-0.07 | ||
| Q2 24 | $-0.30 | — | ||
| Q1 24 | $-1.03 | — | ||
| Q4 23 | $0.80 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $120.0K | $2.7M |
| 总债务越低越好 | $35.7M | — |
| 股东权益账面价值 | $-20.1M | $6.6M |
| 总资产 | $114.2M | $16.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CELUROLR
| Q3 25 | $120.0K | $2.7M | ||
| Q2 25 | $863.0K | $2.7M | ||
| Q1 25 | $293.0K | $3.5M | ||
| Q4 24 | $738.0K | — | ||
| Q3 24 | $133.0K | $1.3M | ||
| Q2 24 | $467.0K | — | ||
| Q1 24 | $1.9M | — | ||
| Q4 23 | $227.0K | — |
总债务CELUROLR
| Q3 25 | $35.7M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
股东权益CELUROLR
| Q3 25 | $-20.1M | $6.6M | ||
| Q2 25 | $-25.5M | $2.6M | ||
| Q1 25 | $-5.5M | $2.8M | ||
| Q4 24 | $8.8M | — | ||
| Q3 24 | $17.3M | $-779.0K | ||
| Q2 24 | $27.8M | — | ||
| Q1 24 | $31.2M | — | ||
| Q4 23 | $41.0M | — |
总资产CELUROLR
| Q3 25 | $114.2M | $16.0M | ||
| Q2 25 | $120.3M | $12.3M | ||
| Q1 25 | $128.9M | $12.8M | ||
| Q4 24 | $132.7M | — | ||
| Q3 24 | $128.8M | $12.9M | ||
| Q2 24 | $135.5M | — | ||
| Q1 24 | $143.8M | — | ||
| Q4 23 | $143.9M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-4.2M | $-78.0K |
| 自由现金流经营现金流 - 资本支出 | — | $-90.0K |
| 自由现金流率自由现金流/营收 | — | -1.4% |
| 资本支出强度资本支出/营收 | — | 0.2% |
| 现金转化率经营现金流/净利润 | — | -0.02× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CELUROLR
| Q3 25 | $-4.2M | $-78.0K | ||
| Q2 25 | $-999.0K | $-840.0K | ||
| Q1 25 | $-3.0M | $-3.6M | ||
| Q4 24 | $1.6M | — | ||
| Q3 24 | $-144.0K | — | ||
| Q2 24 | $-3.4M | — | ||
| Q1 24 | $-4.4M | — | ||
| Q4 23 | $-4.3M | — |
自由现金流CELUROLR
| Q3 25 | — | $-90.0K | ||
| Q2 25 | — | $-845.0K | ||
| Q1 25 | — | $-3.6M | ||
| Q4 24 | $1.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-3.5M | — | ||
| Q1 24 | $-4.4M | — | ||
| Q4 23 | $-4.9M | — |
自由现金流率CELUROLR
| Q3 25 | — | -1.4% | ||
| Q2 25 | — | -12.2% | ||
| Q1 25 | — | -53.5% | ||
| Q4 24 | 8.3% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -28.7% | — | ||
| Q1 24 | -30.3% | — | ||
| Q4 23 | -40.6% | — |
资本支出强度CELUROLR
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | 0.5% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.3% | — | ||
| Q1 24 | 0.3% | — | ||
| Q4 23 | 4.8% | — |
现金转化率CELUROLR
| Q3 25 | — | -0.02× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | -0.45× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CELU
| License Royalty And Other | $2.9M | 56% |
| Degenerative Disease | $2.2M | 42% |
ROLR
| Net Gaming Revenue | $4.9M | 77% |
| Net Revenue Noncore Services | $1.4M | 23% |
